

COVID-19 TESTS WHEN YOU NEED THEM

Abbott is creating tests to help detect the SARS-CoV-2 virus and better understand the spread of COVID-19

Whether you were recently infected with the virus or have recovered from an exposure, our tests span the COVID-19 infection. The more we know about who is infected and who has recovered, the more steps we can take to curb the pandemic and return to a new normal.

THE INFECTION CYCLE OF THE SARS-CoV-2 VIRUS¹⁻⁵



VIRAL RNA	ANTIGEN	ANTIBODY
When the virus enters your body,	As the virus multiplies, the body	As your body starts to fight off infection,
it starts multiplying, and you may	begins to react to the viral antigens,	your immune system produces IgM and
or may not have symptoms.	possibly resulting in symptoms.	IgG antibodies.



VIRAL RNA

As the virus multiplies, levels of its molecular genetic material (RNA) rise, peak around 1 week, then fall off around 2 weeks.



MOLECULAR TESTS

Larger testing instruments, such as the m2000 RealTime System and Alinity m System, can be found in labs that run higher volumes of patient samples. The ID NOW rapid test is portable and can be used at the point of care. Molecular tests are usually performed via a nasal or throat swab.



ANTIGEN

Levels of antigens (which are nucleoproteins) rise, peak, then fall off around 2 weeks.

Ĺ	
	88 🛯 📊
	II)
Bi	naxNOW
COVID	-19 Ag CARD

ANTIGEN TESTS

BinaxNOW COVID-19 Ag is a rapid antigen test that is highly portable, reliable and easy to use for mass testing of active infections. Samples are collected using a nasal swab.



IgM AND IgG ANTIBODIES

IgG and IgM antibodies generally appear ≥ 14 days after infection and approximately 5-7 days after symptom onset.

ARCHITECT i1000SR and	Alinity i

SEROLOGY TESTS

i2000SR

Serology tests can be run on larger testing instruments, such as the ARCHITECT and Alinity i. Serology tests are performed using a blood sample.

in ABBOTT 📅 ABBOTTGLOBAL

f ABBOTT

REFERENCES: 1. Current performance of COVID-19 test methods and devices and proposed performance criteria, Working document of Commission services. European Commission, April 16, 2020. **2.** Tan W, Lu Y, Zhang J, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. medRxiv; 2020. DOI: 10.1101/2020.03.24.20042382. **3.** Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin Infect Dis.* 2020;71(15):778-785. doi:10.1093/cid/ciaa310 **4.** Long, Q., Liu, B., Deng, H. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med* 26, 845-848 (2020). https://doi.org/10.1038/s41591-020-0897-1 **5.** Chaplin DD. Overview of the immune response. *J Allergy Clin Immunol.* 2010;125(2 Suppl 2):S3-S23. doi:10.1016/j.jaci.2009.12.980

DISCLAIMERS: Time periods listed for each phase of infection are general estimates and not indicative of a person's immune reaction to SARS-CoV-2. The Infection Cycle diagram represents current understanding of the SARS-CoV-2 virus. As our understanding evolves, this diagram may change. The following tests have received FDA Emergency Use Authorization and have not been FDA cleared or approved: RealTime SARS-CoV-2, Alinity m SARS-CoV-2, SARS-CoV-2 IgG and Advise Dx SARS-CoV-2 IgM assays for use on ARCHITECT and Alinity i, ID NOW COVID-19 and BinaxNOW COVID-19 Ag Card. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of *in vitro* diagnostic tests for detection of proteins from or antibodies against SARS-CoV-2, not for any other viruses or pathogens, under section 564(b)(1) of the act, 21 U.S.C. § 360bb-3(b)(1), unless the authorization is terminated or revoked sooner. ARCHITECT is a class 1 laser product. © 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.

ABBOTTNEWS

► ABBOTT